KalVista Pharmaceuticals, Inc. (KALV) closed the last trading session at $15.24, gaining 2.6% over the past four weeks, but ...

Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, ...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.

Short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) decreased during the last reporting period, falling from 10.06M to 10.04M. This put 22.45% of the company's publicly available shares short ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Okta Inc (Symbol: OKTA), where a total of 142,673 contracts have traded so far, ...

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat ...

KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in ...